Display options
Cite
Heebøll S, Thomsen KL, Pedersen SB, et al. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol. 2014;6(4):188-98doi: 10.4254/wjh.v6.i4.188.
Heebøll, S., Thomsen, K. L., Pedersen, S. B., Vilstrup, H., George, J., & Grønbæk, H. (2014). Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World journal of hepatology, 6(4), 188-98. https://doi.org/10.4254/wjh.v6.i4.188
Heebøll, Sara, et al. "Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease." World journal of hepatology vol. 6,4 (2014): 188-98. doi: https://doi.org/10.4254/wjh.v6.i4.188
Heebøll S, Thomsen KL, Pedersen SB, Vilstrup H, George J, Grønbæk H. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol. 2014 Apr 27;6(4):188-98. doi: 10.4254/wjh.v6.i4.188. PMID: 24799987; PMCID: PMC4009474.
Copy Download .nbib Format: NLM
Share it on

World J Hepatol. 2014 Apr 27;6(4):188-98. doi: 10.4254/wjh.v6.i4.188.

Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease.

World journal of hepatology

Sara Heebøll, Karen Louise Thomsen, Steen B Pedersen, Hendrik Vilstrup, Jacob George, Henning Grønbæk

Affiliations

  1. Sara Heebøll, Karen Louise Thomsen, Hendrik Vilstrup, Henning Grønbæk, Department of Hepatology and Gastroenterology, Aarhus University Hospital, 8000 Aarhus C, Denmark.

PMID: 24799987 PMCID: PMC4009474 DOI: 10.4254/wjh.v6.i4.188

Abstract

The prevalence of obesity and related conditions like non-alcoholic fatty liver disease (NAFLD) is increasing worldwide and therapeutic options are limited. Alternative treatment options are therefore intensively sought after. An interesting candidate is the natural polyphenol resveratrol (RSV) that activates adenosinmonophosphate-activated protein kinase (AMPK) and silent information regulation-2 homolog 1 (SIRT1). In addition, RSV has known anti-oxidant and anti-inflammatory effects. Here, we review the current evidence for RSV-mediated effects on NAFLD and address the different aspects of NAFLD and non-alcoholic steatohepatitis (NASH) pathogenesis with respect to free fatty acid (FFA) flux from adipose tissue, hepatic de novo lipogenesis, inadequate FFA β-oxidation and additional intra- and extrahepatic inflammatory and oxidant hits. We review the in vivo evidence from animal studies and clinical trials. The abundance of animal studies reports a decrease in hepatic triglyceride accumulation, liver weight and a general improvement in histological fatty liver changes, along with a reduction in circulating insulin, glucose and lipid levels. Some studies document AMPK or SIRT1 activation, and modulation of relevant markers of hepatic lipogenesis, inflammation and oxidation status. However, AMPK/SIRT1-independent actions are also likely. Clinical trials are scarce and have primarily been performed with a focus on overweight/obese participants without a focus on NAFLD/NASH and histological liver changes. Future clinical studies with appropriate design are needed to clarify the true impact of RSV treatment in NAFLD/NASH patients.

Keywords: AMP-activated protein kinase; Animal studies; Anti-inflammatory agents; Anti-oxidants; Clinical trial; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Resveratrol; Silent information regulation-2 homolog 1; Steatosis

References

  1. Scand J Gastroenterol. 2009;44(7):853-60 - PubMed
  2. Cell Metab. 2009 Apr;9(4):327-38 - PubMed
  3. J Hepatol. 2008 Dec;49(6):1019-28 - PubMed
  4. Liver Int. 2007 Jun;27(5):708-15 - PubMed
  5. Acta Pharmacol Sin. 2008 Jun;29(6):698-706 - PubMed
  6. Gastroenterology. 2011 Oct;141(4):1249-53 - PubMed
  7. Am J Clin Nutr. 2005 Jul;82(1 Suppl):222S-225S - PubMed
  8. J Gerontol A Biol Sci Med Sci. 2011 Mar;66(3):264-78 - PubMed
  9. Ecotoxicol Environ Saf. 2010 Jul;73(5):1078-83 - PubMed
  10. Clin Rev Allergy Immunol. 2009 Feb;36(1):4-12 - PubMed
  11. Genes Dev. 2010 Jul 1;24(13):1403-17 - PubMed
  12. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9116-21 - PubMed
  13. Int J Obes (Lond). 2010 Oct;34(10):1546-53 - PubMed
  14. PLoS One. 2010 Oct 22;5(10):e13577 - PubMed
  15. Chin J Physiol. 2012 Jun 30;55(3):192-201 - PubMed
  16. Nature. 2003 Sep 11;425(6954):191-6 - PubMed
  17. J Pediatr. 2013 Mar;162(3):496-500.e1 - PubMed
  18. Clin Chim Acta. 2011 Jul 15;412(15-16):1297-305 - PubMed
  19. Am Surg. 2009 Feb;75(2):103-12 - PubMed
  20. Diabetes Care. 2007 Jun;30(6):1663-9 - PubMed
  21. Clin Liver Dis. 2004 Aug;8(3):595-617, x - PubMed
  22. Cell. 2006 Dec 15;127(6):1109-22 - PubMed
  23. J Biol Chem. 2010 Oct 29;285(44):33959-70 - PubMed
  24. Cell Metab. 2009 Nov;10(5):392-404 - PubMed
  25. Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15998-6003 - PubMed
  26. Metabolism. 2012 Mar;61(3):424-33 - PubMed
  27. Food Chem Toxicol. 2009 Jun;47(6):1362-7 - PubMed
  28. Nutrition. 2013 Mar;29(3):562-7 - PubMed
  29. Histochem Cell Biol. 2011 Oct;136(4):475-89 - PubMed
  30. Hepat Mon. 2013 Apr 09;13(4):e7233 - PubMed
  31. Nutr Clin Pract. 2011 Oct;26(5):565-76 - PubMed
  32. Expert Opin Drug Saf. 2012 Jul;11(4):565-79 - PubMed
  33. Can J Physiol Pharmacol. 2012 Feb;90(2):237-42 - PubMed
  34. Ann Med. 2011 May;43(3):198-211 - PubMed
  35. Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):445-51 - PubMed
  36. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12737-42 - PubMed
  37. Hepatology. 2010 Aug;52(2):774-88 - PubMed
  38. Hepatology. 2010 Nov;52(5):1836-46 - PubMed
  39. Diabet Med. 2008 Apr;25(4):476-81 - PubMed
  40. Hepatology. 2000 Apr;31(4):922-31 - PubMed
  41. Pharmacol Res. 2013 Jan;67(1):60-7 - PubMed
  42. Biochem Res Int. 2012;2012:387626 - PubMed
  43. Med Sci Monit. 2011 May;17(5):HY5-9 - PubMed
  44. Hepatology. 2010 Jul;52(1):79-104 - PubMed
  45. Mol Cell Biochem. 2008 Aug;315(1-2):1-7 - PubMed
  46. Nitric Oxide. 2009 Nov-Dec;21(3-4):216-25 - PubMed
  47. Nat Rev Immunol. 2003 Jan;3(1):23-35 - PubMed
  48. Obes Surg. 2010 May;20(5):633-9 - PubMed
  49. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD007176 - PubMed
  50. Cancer Sci. 2010 Feb;101(2):488-93 - PubMed
  51. J Proteome Res. 2012 Oct 5;11(10):4961-71 - PubMed
  52. Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):233-44 - PubMed
  53. Lipids Health Dis. 2012 May 20;11:56 - PubMed
  54. Annu Rev Nutr. 2012 Aug 21;32:17-33 - PubMed
  55. BMC Syst Biol. 2009 Mar 10;3:31 - PubMed
  56. Expert Opin Emerg Drugs. 2013 Sep;18(3):279-90 - PubMed
  57. Biochem Biophys Res Commun. 2008 Feb 29;367(1):190-4 - PubMed
  58. Mol Cell. 2007 Oct 12;28(1):91-106 - PubMed
  59. Nat Clin Pract Endocrinol Metab. 2008 Nov;4(11):619-26 - PubMed
  60. Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H18-24 - PubMed
  61. Diabetol Metab Syndr. 2013 May 31;5:29 - PubMed
  62. Genes Dev. 1999 Oct 1;13(19):2570-80 - PubMed
  63. Zhonghua Yi Xue Za Zhi. 2007 May 29;87(20):1434-7 - PubMed
  64. Nature. 2006 Nov 16;444(7117):337-42 - PubMed
  65. World J Hepatol. 2013 Sep 27;5(9):470-8 - PubMed
  66. J Biol Chem. 2002 Mar 29;277(13):11019-25 - PubMed
  67. Aging (Albany NY). 2013 Jul;5(7):495-506 - PubMed
  68. Liver Int. 2010 Jul;30(6):795-808 - PubMed
  69. Front Biosci (Landmark Ed). 2009 Jan 01;14:19-44 - PubMed
  70. Aging (Albany NY). 2010 Jun;2(6):315-6 - PubMed
  71. Mol Nutr Food Res. 2012 Aug;56(8):1282-91 - PubMed
  72. Diabetes. 2013 Apr;62(4):1186-95 - PubMed
  73. Diabetes Care. 2012 Apr;35(4):717-22 - PubMed
  74. AAPS J. 2013 Jul;15(3):744-52 - PubMed
  75. Liver Int. 2010 Sep;30(8):1103-14 - PubMed
  76. Pharmacol Res. 2012 Sep;66(3):260-8 - PubMed
  77. Food Chem Toxicol. 2013 Feb;52:12-8 - PubMed
  78. Mol Nutr Food Res. 2011 Aug;55(8):1197-206 - PubMed
  79. Genes Dev. 2000 Nov 15;14(22):2819-30 - PubMed
  80. J Gastroenterol. 2012 Mar;47(3):215-25 - PubMed
  81. Semin Liver Dis. 2008 Nov;28(4):360-9 - PubMed
  82. Arch Surg. 2011 May;146(5):556-64 - PubMed
  83. Nutr Res. 2012 Sep;32(9):701-8 - PubMed
  84. Cell Metab. 2011 Nov 2;14(5):612-22 - PubMed
  85. World J Hepatol. 2013 Apr 27;5(4):160-9 - PubMed
  86. Nutrition. 2013 Nov-Dec;29(11-12):1374-80 - PubMed
  87. Biochem Pharmacol. 2011 Jun 1;81(11):1343-51 - PubMed
  88. Oxid Med Cell Longev. 2013;2013:793525 - PubMed
  89. World J Gastroenterol. 2010 Aug 14;16(30):3731-42 - PubMed
  90. J Appl Toxicol. 2008 Jan;28(1):35-43 - PubMed
  91. Ann N Y Acad Sci. 2011 Jan;1215:34-9 - PubMed
  92. Eur J Pharm Sci. 2013 May 13;49(2):251-7 - PubMed
  93. J Nutr Biochem. 2013 Jun;24(6):960-6 - PubMed
  94. Diabetes. 2012 Jun;61(6):1444-54 - PubMed
  95. Cell. 2012 Feb 3;148(3):421-33 - PubMed
  96. Br J Nutr. 2012 Dec 28;108(12):2166-75 - PubMed
  97. Nat Commun. 2010 Apr 12;1:3 - PubMed
  98. Biochim Biophys Acta. 2011 Jul;1812(7):719-31 - PubMed
  99. Nature. 2001 Mar 8;410(6825):227-30 - PubMed
  100. J Nutr Metab. 2011;2011:525094 - PubMed
  101. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85 - PubMed
  102. Diabetes. 2006 Aug;55(8):2180-91 - PubMed
  103. Cell Metab. 2012 May 2;15(5):675-90 - PubMed
  104. JAMA. 2011 Oct 12;306(14):1549-56 - PubMed
  105. Cell Metab. 2012 Nov 7;16(5):658-64 - PubMed
  106. Biochem Pharmacol. 2009 Mar 15;77(6):1053-63 - PubMed
  107. Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12861-6 - PubMed
  108. Nutr Metab (Lond). 2008 Jun 12;5:17 - PubMed
  109. Chem Biol Interact. 2010 Jul 30;186(2):200-10 - PubMed
  110. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13656-61 - PubMed
  111. BMC Gastroenterol. 2008 Sep 09;8:40 - PubMed
  112. Arch Pharm Res. 2010 Jun;33(6):925-32 - PubMed
  113. Br J Nutr. 2012 Jan;107(2):202-10 - PubMed
  114. J Hepatol. 2013 May;58(5):904-10 - PubMed
  115. Cell Metab. 2011 Apr 6;13(4):376-388 - PubMed
  116. J Clin Invest. 2005 May;115(5):1343-51 - PubMed
  117. Food Chem Toxicol. 2014 Jan;63:166-73 - PubMed
  118. J Biol Chem. 2008 Jul 18;283(29):20015-26 - PubMed
  119. Eur J Gastroenterol Hepatol. 2010 Jan;22(1):18-23 - PubMed
  120. Diabetes. 2010 Mar;59(3):554-63 - PubMed

Publication Types